ArticlePloS one2015
MiR-506 is down-regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT1.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 67 citations in OpenAlex.
- Retraction: MiR-506 Is Down-Regulated in Clear Cell Renal Cell Carcinoma and Inhibits Cell Growth and Metastasis via Targeting FLOT1.PloS one · 2026Article
- Retraction: Long non-coding RNA TUG1 promotes cervical cancer progression by regulating the miR-138-5p-SIRT1 axis.Oncotarget · 2025Article
- Study of MicroRNA Cluster Located on Chromosome X in Serum and Breast Cancer Tissue.Biochemical genetics · 2024Article
- MiREx: mRNA levels prediction from gene sequence and miRNA target knowledge.BMC bioinformatics · 2023Article
- The roles of FLOT1 in human diseases (Review).Molecular medicine reports · 2023Review
- MiR-506 Promotes Antitumor Immune Response in Pancreatic Cancer by Reprogramming Tumor-Associated Macrophages toward an M1 Phenotype.Biomedicines · 2023Article
- FLOT1 promotes gastric cancer progression and metastasis through BCAR1/ERK signaling.International journal of biological sciences · 2023Article
- Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.Molecular biology reports · 2022Review
- MicroRNA-506-3p inhibits ovarian cancer metastasis by down-regulating the expression of EZH2.Journal of Cancer · 2022Article
- miR-92a promotes proliferation and inhibits apoptosis of prostate cancer cells through the PTEN/Akt signaling pathway.The Libyan journal of medicine · 2021Article
- ChrXq27.3 miRNA cluster functions in cancer development.Journal of experimental & clinical cancer research : CR · 2021Review
- Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.International journal of molecular sciences · 2020Article
- Review
- CircRNA-UBE2G1 regulates LPS-induced osteoarthritis through miR-373/HIF-1a axis.Cell cycle (Georgetown, Tex.) · 2020Article
- Flotillin membrane domains in cancer.Cancer metastasis reviews · 2020Review
- Circ-SAR1A Promotes Renal Cell Carcinoma Progression Through miR-382/YBX1 Axis.Cancer management and research · 2020Article
- Long Non-Coding RNA TUG1 Promotes Cell Proliferation and Inhibits Cell Apoptosis, Autophagy in Clear Cell Renal Cell Carcinoma via MiR-31-5p/FLOT1 Axis.OncoTargets and therapy · 2020Article
- Long Non-Coding RNACancer management and research · 2020Article
- miR-155 Regulates the Proliferation of Glioma Cells Through PI3K/AKT Signaling.Frontiers in neurology · 2020Article
- lncRNA PDIA3P regulates cell proliferation and invasion in non-small cell lung cancer.Experimental and therapeutic medicine · 2019Article
Corrections and comments
- Correction · 2015-05-26Error in Text · Updated to Retraction · · See also: https://pubpeer.com/publications/E1E121E49D0043CE889D17D3A19962
- Retraction · 2026-03-30Concerns/Issues about Results and/or Conclusions · Duplication of/in Image · Euphemisms for Duplication · Euphemisms for Plagiarism · Plagiarism of Image · Upgrade/Update of Prior Notice(s) · · See also: https://pubpeer.com/publications/E1E121E49D0043CE889D17D3A19962
- Erratum issuedCorrection: MiR-506 Is Down-Regulated in Clear Cell Renal Cell Carcinoma and Inhibits Cell Growth and Metastasis via Targeting FLOT1.2015 · Zhang, Hai-ming [corrected to Zhang, Hai-Min]
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome microRNAs (miRNAs) are abnormally expressed in cancer and contribute to tumorigenesis. In the present study, we investigated the role of miR-506 in clear cell renal cell carcinoma (ccRCC).
methodsmiR-506 expression was detected in renal cancer cell lines 786-O, ACHN, Caki-1, and Caki-2 and ccRCC specimens by quantitative real-time-PCR. We assessed the association of miR-506 expression with pathology and prognosis in ccRCC patients. We over-expressed and knocked-down miR-506 expression in two renal cancer cell lines, 786-O and ACHN, and assessed the impact on cell proliferation, migration and invasion. A luciferase reporter assay was conducted to confirm the target gene of miR-506 in renal cancer cell lines.
resultsmiR-506 was significantly down-regulated in renal cancer cell lines and ccRCC specimens. Low miR-506 expression in ccRCC specimens was associated with an advanced clinical stage and poor prognosis. miR-506 expression was an independent prognostic marker of overall ccRCC patient survival in a multivariate analysis. Over-expression of miR-506 in renal cancer cells decreased cell growth and metastasis, In contrast, down-regulation of miR-506 expression promoted renal cancer cell growth and metastasis. FLOT1, a potential target gene of miR-506, was inversely correlated with miR-506 expression in ccRCC tissues. Consistent with the effect of miR-506, knockdown of FLOT1 by siRNA inhibited cell malignant behaviors. Rescue of FLOT1 expression partially restored the effects of miR-506.
conclusionsmiR-506 exerts its anti-cancer function by directly targeting FLOT1 in renal cancer, indicating a potential novel therapeutic role in renal cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.